MedPath

Effect of Chahel tablets in patients having Stress Issues.

Phase 4
Conditions
Health Condition 1: F419- Anxiety disorder, unspecified
Registration Number
CTRI/2023/10/058410
Lead Sponsor
Ambic Ayurved India Pvt. Ltd.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1.Subject from 18-65 years of age.

2.Subject suffering from one or multiple mental health Issues from- anxiety, insomnia, depression etc;

3.Subjects that are able to give written informed consent in a manner approved by the institutional ethics committee and comply with the requirements of the study.

4.Subject willing to avoid participation in any other interventional clinical trial for the duration of the study.

Exclusion Criteria

1.Have used, are using, or are planning to use immunosuppressive or immunomodulatory medication (i.e., biologics), including oral or parenteral corticosteroids.

2.Subjects that have participated in any other interventional clinical trial in the previous 30 days.

3.Subjects with known sensitivity to any of the constituents of the investigational product.

Study & Design

Study Type
PMS
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Reduction in Stress Issues calculated as SGA <br/ ><br>Change in Cortisol level <br/ ><br>Change in EEG Assessment calculated as alpha, beta and thetaTimepoint: Time frame 0-30 days <br/ ><br>Time frame 0-30 days <br/ ><br>Time frame 0-30 days
Secondary Outcome Measures
NameTimeMethod
ot applicableTimepoint: Not applicable
© Copyright 2025. All Rights Reserved by MedPath